NASDAQ:HOWL Werewolf Therapeutics (HOWL) Stock Price, News & Analysis → The 'Smart Money' Is Ready for May 1st Are You? (From Stansberry Research) (Ad) Free HOWL Stock Alerts $6.39 -0.05 (-0.78%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$6.24▼$6.6550-Day Range$4.69▼$7.9152-Week Range$1.57▼$8.19Volume81,697 shsAverage Volume198,183 shsMarket Capitalization$277.01 millionP/E RatioN/ADividend YieldN/APrice Target$11.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Werewolf Therapeutics alerts: Email Address Werewolf Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside80.0% Upside$11.50 Price TargetShort InterestHealthy1.61% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.77Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.38) to ($1.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.74 out of 5 starsMedical Sector406th out of 907 stocksPharmaceutical Preparations Industry180th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingWerewolf Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageWerewolf Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.61% of the float of Werewolf Therapeutics has been sold short.Short Interest Ratio / Days to CoverWerewolf Therapeutics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Werewolf Therapeutics has recently increased by 9.26%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldWerewolf Therapeutics does not currently pay a dividend.Dividend GrowthWerewolf Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HOWL. Previous Next 3.2 News and Social Media Coverage News SentimentWerewolf Therapeutics has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Werewolf Therapeutics this week, compared to 1 article on an average week.Search Interest7 people have searched for HOWL on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Werewolf Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -55% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Werewolf Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders21.10% of the stock of Werewolf Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions64.84% of the stock of Werewolf Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Werewolf Therapeutics are expected to decrease in the coming year, from ($1.38) to ($1.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Werewolf Therapeutics is -6.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Werewolf Therapeutics is -6.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioWerewolf Therapeutics has a P/B Ratio of 2.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Werewolf Therapeutics Stock (NASDAQ:HOWL)Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.Read More HOWL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HOWL Stock News HeadlinesApril 24, 2024 | globenewswire.comWerewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingApril 23, 2024 | finance.yahoo.comWerewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual MeetingApril 25, 2024 | Stansberry Research (Ad)The "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. April 23, 2024 | globenewswire.comWerewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual MeetingApril 19, 2024 | markets.businessinsider.comBuy Rating Affirmed for Werewolf Therapeutics on Promising PREDATOR Platform Prospects and Strong Pipeline PotentialApril 12, 2024 | msn.comWhy Howl's turn-based tactics are ideal for mobileApril 5, 2024 | globenewswire.comWerewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual MeetingApril 4, 2024 | seekingalpha.comWerewolf Therapeutics: In The Hunt For Success In The Cytokine SpaceApril 25, 2024 | Stansberry Research (Ad)The "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. April 4, 2024 | globenewswire.comWerewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual MeetingMarch 15, 2024 | morningstar.comWerewolf Therapeutics Inc HOWLMarch 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Werewolf Therapeutics with Anticipated Surge on WTX-124 Phase 1 Data ReleaseMarch 9, 2024 | finance.yahoo.comWerewolf Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 7, 2024 | markets.businessinsider.comBuy Rating Reiterated for Werewolf Therapeutics Amid Promising INDUKINE Platform DevelopmentsMarch 7, 2024 | investorplace.comHOWL Stock Earnings: Werewolf Therapeutics Beats EPS, Misses Revenue for Q4 2023March 7, 2024 | benzinga.comRecap: Werewolf Therapeutics Q4 EarningsMarch 7, 2024 | finanznachrichten.deWerewolf Therapeutics, Inc.: Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 7, 2024 | globenewswire.comWerewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 6, 2024 | finance.yahoo.comHOWL Mar 2024 2.500 putMarch 6, 2024 | globenewswire.comWerewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma ConferenceMarch 5, 2024 | globenewswire.comWerewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024February 27, 2024 | finance.yahoo.comWerewolf Therapeutics, Inc. (HOWL)February 21, 2024 | benzinga.comWerewolf Therapeutics Stock (NASDAQ:HOWL), Short Interest ReportFebruary 20, 2024 | yahoo.comDo wolf reintroduction programs restore ecosystems? It's not that simple, researchers sayFebruary 20, 2024 | yahoo.comCool Video Captures Rare Sight of Wolf Pack Trekking Through Deep Snow in ChinaFebruary 12, 2024 | msn.comWolves howl in different accentsFebruary 10, 2024 | msn.comWerewolf Therapeutics Expands Offering with $25M Stock SaleSee More Headlines Receive HOWL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Werewolf Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today4/25/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:HOWL CUSIPN/A CIK1785530 Webwerewolftx.com Phone617-952-0555FaxN/AEmployees47Year FoundedN/APrice Target and Rating Average Stock Price Target$11.50 High Stock Price Target$15.00 Low Stock Price Target$9.00 Potential Upside/Downside+80.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,370,000.00 Net Margins-187.37% Pretax Margin-187.37% Return on Equity-32.25% Return on Assets-20.43% Debt Debt-to-Equity Ratio0.29 Current Ratio7.14 Quick Ratio7.14 Sales & Book Value Annual Sales$19.94 million Price / Sales13.89 Cash FlowN/A Price / Cash FlowN/A Book Value$3.08 per share Price / Book2.07Miscellaneous Outstanding Shares43,350,000Free Float34,201,000Market Cap$277.01 million OptionableOptionable Beta0.70 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Daniel J. Hicklin Ph.D. (Age 60)Founder, CEO, President, Secretary & Director Comp: $928.26kKey CompetitorsRAPT TherapeuticsNASDAQ:RAPTEnanta PharmaceuticalsNASDAQ:ENTAVanda PharmaceuticalsNASDAQ:VNDAESSA PharmaNASDAQ:EPIXNanobiotixNASDAQ:NBTXView All CompetitorsInstitutional OwnershipDenali Advisors LLCBought 26,600 shares on 4/19/2024Ownership: 0.061%PFM Health Sciences LPBought 909,895 shares on 2/15/2024Ownership: 8.529%Lighthouse Investment Partners LLCBought 22,472 shares on 2/14/2024Ownership: 0.055%Certuity LLCBought 10,000 shares on 2/5/2024Ownership: 0.028%Financial Perspectives IncBought 3,000 shares on 2/1/2024Ownership: 0.019%View All Institutional Transactions HOWL Stock Analysis - Frequently Asked Questions Should I buy or sell Werewolf Therapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Werewolf Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HOWL shares. View HOWL analyst ratings or view top-rated stocks. What is Werewolf Therapeutics' stock price target for 2024? 2 brokerages have issued 12 month target prices for Werewolf Therapeutics' shares. Their HOWL share price targets range from $9.00 to $15.00. On average, they predict the company's share price to reach $11.50 in the next year. This suggests a possible upside of 80.0% from the stock's current price. View analysts price targets for HOWL or view top-rated stocks among Wall Street analysts. How have HOWL shares performed in 2024? Werewolf Therapeutics' stock was trading at $3.86 on January 1st, 2024. Since then, HOWL stock has increased by 65.5% and is now trading at $6.39. View the best growth stocks for 2024 here. Are investors shorting Werewolf Therapeutics? Werewolf Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 472,000 shares, an increase of 9.3% from the March 15th total of 432,000 shares. Based on an average trading volume of 240,200 shares, the short-interest ratio is currently 2.0 days. Approximately 1.6% of the shares of the company are short sold. View Werewolf Therapeutics' Short Interest. When is Werewolf Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our HOWL earnings forecast. How were Werewolf Therapeutics' earnings last quarter? Werewolf Therapeutics, Inc. (NASDAQ:HOWL) released its quarterly earnings data on Thursday, March, 7th. The company reported ($0.33) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.10. The firm earned $1.50 million during the quarter, compared to the consensus estimate of $2.75 million. Werewolf Therapeutics had a negative net margin of 187.37% and a negative trailing twelve-month return on equity of 32.25%. When did Werewolf Therapeutics IPO? Werewolf Therapeutics (HOWL) raised $101 million in an IPO on Friday, April 30th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, SVB Leerink and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager. Who are Werewolf Therapeutics' major shareholders? Werewolf Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Denali Advisors LLC (0.06%). Insiders that own company stock include Bioventures 2014 LP Mpm, Ra Capital Management, LP and Reid Leonard. View institutional ownership trends. How do I buy shares of Werewolf Therapeutics? Shares of HOWL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HOWL) was last updated on 4/25/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyFed launches fourth dollar overhaulStansberry ResearchExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersMan Who Predicted 2008: “This Will be Worse.”AltimetryBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Werewolf Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
